Patents by Inventor Tianlei Ying
Tianlei Ying has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101639Abstract: Provided is an Fc monomer polypeptide, comprising CH2 and CH3 domains, the Fc monomer polypeptide comprising an amino acid sequence shown in SEQ ID NO: 1; X0 is L or S; X1 is any one amino acid among C, G, S, L, N, D, F, I, V, Y, Q, K, E, M, T or R; X2 is any one amino acid among H, L, Q, N, D, Y, R, C, G, S, F, T, I, V, A, K or M; X3 is any one amino acid among P, N, T, I, S, M, Q, R, L, G, V, A, E, D, Y, F, H or K; X4 is any one amino acid among K, N, S, I, M, E, Q, L, V, A, H, D, Y, F or T; and X5 is M or Y Beneficial effects: a class of IgG Fc monomer polypeptides is obtained, the molecular weight thereof is only half of that of a wild type Fc region, the FcRn binding function of an antibody is reserved, and efficient expression in prokaryotic cells can be achieved.Type: ApplicationFiled: April 26, 2023Publication date: March 28, 2024Inventors: Tianlei Ying, Chunyu Wang
-
Publication number: 20210206847Abstract: An IgG1 Fc monomer, a preparation method therefor and an application thereof. Causing an Fc dimer of a novel IgG1 Fc monomer sequence for which an antibody IgG1 constant region is modified to become an Fc monomer by means of the modification on a human antibody IgG1 constant region Fc that uses antibody engineering technology, and maintaining an FcRn binding function; the present application has the feature of very low non-specific binding with unrelated proteins, and the main features of the Fc monomer comprise the T366, L368, P395, and K409 positions in a CH3 region of the constant region of the antibody having mutations, and the monomer being highly efficiently expressed in prokaryotic cells; the monomer may bind to FcRn by using a pH-dependent specific binding mode, and has the feature of very low non-specific binding.Type: ApplicationFiled: October 24, 2018Publication date: July 8, 2021Inventors: Tianlei YING, Chunyu WANG
-
Publication number: 20210171645Abstract: The present invention provides new, fully human EphA4 monoclonal antibodies with distinct binding characteristics. Also disclosed are antigen binding fragments of these antibodies, bispecific forms of these antibodies, and conjugates of these antibodies. In addition, nucleic acids encoding these antibodies, antigen binding fragments, bispecific antibodies and conjugates are disclosed. These monoclonal antibodies, antigen binding fragments, bispecific antibodies, conjugates, nucleic acids and vectors are of use for identifying and treating a subject with a disease or condition involving abnormal EphA4-mediated signaling.Type: ApplicationFiled: February 15, 2021Publication date: June 10, 2021Inventors: Nancy Yuk-Yu Ip, Kit Yu Fu, Wing Yu Fu, Dimiter S. Dimitrov, Tianlei Ying
-
Patent number: 10934360Abstract: The present invention provides new, fully human EphA4 monoclonal antibodies with distinct binding characteristics. Also disclosed are antigen binding fragments of these antibodies, bispecific forms of these antibodies, and conjugates of these antibodies. In addition, nucleic acids encoding these antibodies, antigen binding fragments, bispecific antibodies and conjugates are disclosed. These monoclonal antibodies, antigen binding fragments, bispecific antibodies, conjugates, nucleic acids and vectors are of use for identifying and treating a subject with a disease or condition involving abnormal EphA4-mediated signaling.Type: GrantFiled: July 31, 2015Date of Patent: March 2, 2021Assignees: The Hong Kong University of Science and Technology, THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Nancy Yuk-Yu Ip, Kit Yu Fu, Wing Yu Fu, Dimiter S. Dimitrov, Tianlei Ying
-
Patent number: 10633447Abstract: Fc domains and CH3 domains are disclosed that bind the neonatal Fc (FcRn) receptor and are at least 99% monomeric. Monomeric Fc domain molecules and CH3 domain molecules are disclosed herein that include a monomeric Fc domain or a monomeric CH3 domain and an effector molecule. In some embodiments, the monomeric Fc or monomeric CH3 domain include amino acid substitutions and/or CDR insertions in the beta strands such that they specifically bind an antigen. Methods for using these monomeric Fc domains, monomeric CH3 domains, monomeric Fc domain molecules and CH3 domain molecules are also provided.Type: GrantFiled: May 9, 2017Date of Patent: April 28, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Tianlei Ying
-
Patent number: 10472412Abstract: The invention provides a construct comprising two or more fusion proteins of Formulas (I)-(IV): A-(optional linker)-C-(optional linker)-B (Formula I), B-(optional linker)-D-(optional linker)-E-(optional linker)-B (Formula II), A-(optional linker)-C (Formula III), and B-(optional linker)-D-(optional linker)-E (Formula IV), wherein A denotes an antibody or antibody fragment, B denotes a single domain CD4, C denotes an immunoglobulin light chain constant region D denotes an immunoglobulin heavy chain constant region, and E denotes an Fc region or a portion thereof that is optionally defucosylated.Type: GrantFiled: December 16, 2015Date of Patent: November 12, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Fudan UniversityInventors: Dimiter S. Dimitrov, Weizao Chen, Tianlei Ying
-
Patent number: 10421802Abstract: The invention provides polypeptides (e.g., antibodies) and fusion proteins that target a epitope in the receptor binding domain (RBD) of the spike (S) glycoprotein of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The polypeptides and fusion proteins can be used to treat and prevent MERS-CoV infection in mammals.Type: GrantFiled: October 16, 2014Date of Patent: September 24, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Veritech LimitedInventors: Dimiter S. Dimitrov, Tianlei Ying, Tina W. Ju, Kwok Yung Yuen
-
Publication number: 20180118815Abstract: The invention provides a construct comprising two or more fusion proteins of Formulas (I)-(IV): A-(optional linker)-C-(optional linker)-B (Formula I), B-(optional linker)-D-(optional linker)-E-(optional linker)-B (Formula II), A-(optional linker)-C (Formula III), and B-(optional linker)-D-(optional linker)-E (Formula IV), wherein A denotes an antibody or antibody fragment, B denotes a single domain CD4, C denotes an immunoglobulin light chain constant region D denotes an immunoglobulin heavy chain constant region, and E denotes an Fc region or a portion thereof that is optionally defucosylated.Type: ApplicationFiled: December 16, 2015Publication date: May 3, 2018Applicants: The United States of America, as Represented by the Secretary, Dept. of Health and Human Resources, Fudan UniversityInventors: Dimiter S. Dimitrov, Weizao Chen, Tianlei Ying
-
Publication number: 20170247453Abstract: Fc domains and CH3 domains are disclosed that bind the neonatal Fc (FcRn) receptor and are at least 99% monomeric. Monomeric Fc domain molecules and CH3 domain molecules are disclosed herein that include a monomeric Fc domain or a monomeric CH3 domain and an effector molecule. In some embodiments, the monomeric Fc or monomeric CH3 domain include amino acid substitutions and/or CDR insertions in the beta strands such that they specifically bind an antigen. Methods for using these monomeric Fc domains, monomeric CH3 domains, monomeric Fc domain molecules and CH3 domain molecules are also provided.Type: ApplicationFiled: May 9, 2017Publication date: August 31, 2017Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Dimiter S. Dimitrov, Tianlei Ying
-
Publication number: 20170218075Abstract: The present invention provides new, fully human EphA4 monoclonal antibodies with distinct binding characteristics. Also disclosed are antigen binding fragments of these antibodies, bispecific forms of these antibodies, and conjugates of these antibodies. In addition, nucleic acids encoding these antibodies, antigen binding fragments, bispecific antibodies and conjugates are disclosed. These monoclonal antibodies, antigen binding fragments, bispecific antibodies, conjugates, nucleic acids and vectors are of use for identifying and treating a subject with a disease or condition involving abnormal EphA4-mediated signaling.Type: ApplicationFiled: July 31, 2015Publication date: August 3, 2017Inventors: Nancy Yuk-Yu Ip, Kit Yu Fu, Wing Yu Fu, Dimiter S. Dimitrov, Tianlei Ying
-
Patent number: 9676857Abstract: Fc domains and CH3 domains are disclosed that bind the neonatal Fc (FcRn) receptor and are at least 99% monomeric. Monomeric Fc domain molecules and CH3 domain molecules are disclosed herein that include a monomeric Fc domain or a monomeric CH3 domain and an effector molecule. In some embodiments, the monomeric Fc or monomeric CH3 domain include amino acid substitutions and/or CDR insertions in the beta strands such that they specifically bind an antigen. Methods for using these monomeric Fc domains, monomeric CH3 domains, monomeric Fc domain molecules and CH3 domain molecules are also provided.Type: GrantFiled: March 14, 2013Date of Patent: June 13, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Tianlei Ying
-
Publication number: 20160264647Abstract: The invention provides polypeptides (e.g., antibodies) and fusion proteins that target a epitope in the receptor binding domain (RBD) of the spike (S) glycoprotein of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The polypeptides and fusion proteins can be used to treat and prevent MERS-CoV infection in mammals.Type: ApplicationFiled: October 16, 2014Publication date: September 15, 2016Inventors: Dimiter S. Dimitrov, Tianlei Ying, Tina W. Ju, Kwok Yung Yuen
-
Publication number: 20150050278Abstract: Fc domains and CH3 domains are disclosed that bind the neonatal Fc (FcRn) receptor and are at least 99% monomeric. Monomeric Fc domain molecules and CH3 domain molecules are disclosed herein that include a monomeric Fc domain or a monomeric CH3 domain and an effector molecule. In some embodiments, the monomeric Fc or monomeric CH3 domain include amino acid substitutions and/or CDR insertions in the beta strands such that they specifically bind an antigen. Methods for using these monomeric Fc domains, monomeric CH3 domains, monomeric Fc domain molecules and CH3 domain molecules are also provided.Type: ApplicationFiled: March 14, 2013Publication date: February 19, 2015Inventors: Dimiter S. Dimitrov, Tianlei Ying